Trial · NCT04901325
Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
NCT04901325, Phase 2, Completed, Oregon Health and Science University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG). Trials, record NCT04901325. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04901325
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
- NCT number
- NCT04901325
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 5 participants, actual
- Lead sponsor
- Oregon Health and Science University
- Conditions
- Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma, Skin Ulcer
- Interventions
- Baricitinib
- First posted
- 2021-05-25
- Last updated
- 2025-05-13
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Healing | Week 24 | defined as the proportion of patients with complete re-epithelization, defined as 100% re-epithelialization without any drainage, of the target ulcer at week 24. |
| Secondary | Physician Global Assessment (PGA) | Week 24 | Assessing the proportion of patients that show target ulcer healing in response to study treatment as measured by achieving PGA between 0 and 1 after treatment with baricitinib at week-36 52. This scale has been used in previous trials: 1. 0 = total resolution of target ulcer with no signs of active PG 2. 1= almost completely healed target ulcer with only minimal signs of active PG 3. 2 = evidence of target ulcer healing which involves at least 50% of ulcer/ulcer margin 4. 3 = evidence of target ulcer healing which involves less than 50% of ulcer/margin 5. 4 = no evidence of target healing ulcer |
| Secondary | Percent change in lesion surface area | Week 0 and 24 | The percent change in surface area of target lesion of PG (two-dimensional surface in cm²) using digital photography and acetate tracing at Week 0 and Week 24 |
| Secondary | Mean change in lesion surface area | Week 0 and 24 | The mean change in surface area of target lesion of PG (two-dimensional surface in cm²) using digital photography and acetate tracing |
| Secondary | Mean change in Physician Global Assessment (PGA) | Week 0 and 24 | The mean change in Physician global assessment (PGA) 5-point scale at week 0 to week 24 |
| Secondary | Sustained healing | Week 36 | The proportion of patients with target ulcer that remains healed by week 36 |
| Secondary | Decrease in ulcer area size | Week 24 | The proportion of patients with decrease in ulcer area size of at least 50% after treatment at week 24 |
| Secondary | Time to healing | Over 36-week period of study. | Time to which sterile dressings are not required. |
| Secondary | Time to recurrence (weeks) | 36 weeks | Interval between target lesion healing and further episodes of PG at any site through the study. |
| Secondary | Number of treatment failures | By week 24 | Treatment intolerance, number of patients switching into standard of care or target lesion unhealed. |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers9
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04901325
GET https://conductscience.org/api/trials/v1/NCT04901325/registered